<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474426</article-id><article-id pub-id-type="pmcid-ver">PMC12474426.1</article-id><article-id pub-id-type="pmcaid">12474426</article-id><article-id pub-id-type="pmcaiid">12474426</article-id><article-id pub-id-type="pmid">41012167</article-id><article-id pub-id-type="doi">10.3390/vaccines13090964</article-id><article-id pub-id-type="publisher-id">vaccines-13-00964</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Strategies to Increase Vaccinations in Adult Cancer Patients: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9472-3263</contrib-id><name name-style="western"><surname>Lo Moro</surname><given-names initials="G">Giuseppina</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00964" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Golzio</surname><given-names initials="F">Federica</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Calabrese</surname><given-names initials="SC">Sara Claudia</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5189-1294</contrib-id><name name-style="western"><surname>Scaioli</surname><given-names initials="G">Giacomo</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Basile</surname><given-names initials="A">Alessandro</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siliquini</surname><given-names initials="R">Roberta</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00964" ref-type="aff">2</xref><xref rid="fn1-vaccines-13-00964" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bert</surname><given-names initials="F">Fabrizio</given-names></name><xref rid="af1-vaccines-13-00964" ref-type="aff">1</xref><xref rid="af3-vaccines-13-00964" ref-type="aff">3</xref><xref rid="fn1-vaccines-13-00964" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Simecka</surname><given-names initials="JW">Jerry W.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00964"><label>1</label>Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; <email>federica.golzio@unito.it</email> (F.G.); <email>saraclaudia.calabrese@unito.it</email> (S.C.C.); <email>giacomo.scaioli@unito.it</email> (G.S.); <email>alessandro.basile@unito.it</email> (A.B.); <email>roberta.siliquini@unito.it</email> (R.S.); <email>fabrizio.bert@unito.it</email> (F.B.)</aff><aff id="af2-vaccines-13-00964"><label>2</label>Health Directorate, Azienda Ospedaliera Universitaria City of Health and Science of Turin, 10126 Turin, Italy</aff><aff id="af3-vaccines-13-00964"><label>3</label>Collegium Medicum, University of Social Sciences, 90-113 Lodz, Poland</aff><author-notes><corresp id="c1-vaccines-13-00964"><label>*</label>Correspondence: <email>giuseppina.lomoro@unito.it</email></corresp><fn id="fn1-vaccines-13-00964"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>13</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497676</issue-id><elocation-id>964</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-13-00964.pdf"/><abstract><p>Background/Objectives: Although vaccinations are a priority for patients with cancer, achieving high coverage remains challenging. Evidence on effective strategies in oncology settings is still limited. This systematic review aimed to identify interventions to improve vaccination uptake or reduce hesitancy among cancer patients. Methods: A systematic search was conducted in PubMed, Embase, and Scopus, including studies published up to the end of 2023. The protocol was registered in PROSPERO (CRD42024511008). Results: Out of 10,927 non-duplicate records, 15 studies describing unique interventions were included. All studies were published between 2011 and 2022, primarily conducted in Europe/UK (40%) and in North America (40%). The most common study design was pre-post (60%), and 33.3% included a control group. Most interventions were multi-component (60%) and were classified into three main categories: educational materials/campaigns (46.7%), reminders (40%), and patient counselling (33.3%). Additional components included guideline development in two studies. Some studies also highlighted the importance of specific key figures, such as dedicated professionals, general practitioners, and pharmacists. Interventions mainly targeted patients (40%), with 33.3% addressing both healthcare professionals and patients and 26.7% professionals only. They most frequently concerned vaccinations against influenza and pneumococcal disease (26.7%), pneumococcal disease alone (26.7%), or Coronavirus Disease 2019 (COVID-19) (26.7%). Vaccination uptake was the primary outcome in 86.7% of studies, with 66.7% reporting significant improvements. Conclusions: This review identified a variety of strategies, with education, reminders, and counselling as key components. Multicomponent interventions and those involving both patients and providers were most promising. However, methodological limitations and limited generalizability highlighted the need for more rigorous research.</p></abstract><kwd-group><kwd>cancer patients</kwd><kwd>vaccination</kwd><kwd>systematic review</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00964"><title>1. Introduction</title><p>According to the Global Cancer Observatory, the incidence of new cancer cases in 2022 was almost 20 million worldwide [<xref rid="B1-vaccines-13-00964" ref-type="bibr">1</xref>]. Patients with cancer have a weakened immune system due to both the disease itself and its specific therapies. Consequently, these patients have an increased risk of infections and related complications [<xref rid="B2-vaccines-13-00964" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00964" ref-type="bibr">3</xref>]. In particular, a recent U.S. study showed that the risk of death from infections among cancer patients was three times higher than in the general population [<xref rid="B4-vaccines-13-00964" ref-type="bibr">4</xref>]. Infections are the leading cause of morbidity and mortality among cancer patients, resulting in frequent and prolonged hospitalizations [<xref rid="B5-vaccines-13-00964" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00964" ref-type="bibr">6</xref>]</p><p>Vaccination is an effective strategy to reduce the risk of infection-related complications and deaths [<xref rid="B7-vaccines-13-00964" ref-type="bibr">7</xref>]. Evidence consistently showed that immunization can enhance survival. For instance, in the ASCO COVID-19 registry, patients with cancer who had not received a SARS-CoV-2 vaccine had a 1.60-fold higher risk of death (95% CI 1.26&#8211;2.04) compared with vaccinated individuals [<xref rid="B8-vaccines-13-00964" ref-type="bibr">8</xref>]. A multicenter study reported that influenza vaccination improved overall survival (OS) among patients receiving immune checkpoint inhibitors, with a hazard ratio (HR) of 0.75 (95% CI 0.62&#8211;0.92) and increased disease control rate (OR 1.47, 95% CI 1.11&#8211;1.96) [<xref rid="B9-vaccines-13-00964" ref-type="bibr">9</xref>]. Pneumococcal vaccination also significantly improved OS: in the study by Li et al. the 7-year OS rates were 47.5% in the vaccinated group versus 42.3% in the unvaccinated group (log-rank <italic toggle="yes">p</italic> = 0.0003) [<xref rid="B10-vaccines-13-00964" ref-type="bibr">10</xref>]. In addition to clinical benefits, vaccinations have proven cost-effective in immunocompromised populations. For example, recombinant zoster vaccine in 19,671 U.S. hematopoietic stem cell transplant recipients resulted in total societal cost savings of USD 0.1 million and 109 incremental quality-adjusted life years (QALYs) compared with no vaccine [<xref rid="B11-vaccines-13-00964" ref-type="bibr">11</xref>]. Adding PCV13 to PPSV23 in adults with immunocompromising conditions yielded 1,360 discounted QALYs and net savings of USD 5.2 million [<xref rid="B12-vaccines-13-00964" ref-type="bibr">12</xref>]. Finally, influenza vaccination in working-age cancer patients was also highly cost-effective, with an incremental cost-effectiveness ratio of only USD 224 per QALY gained [<xref rid="B13-vaccines-13-00964" ref-type="bibr">13</xref>].</p><p>Indeed, although the immune response of oncological patients can be persistently suppressed, they can still reach seroprotection in many cases thanks to vaccines, thus making some of the most common infections in cancer patients vaccine-preventable [<xref rid="B14-vaccines-13-00964" ref-type="bibr">14</xref>]. In 2024, the American Society of Clinical Oncology (ASCO) published vaccination guidelines for adult patients with cancer, recommending a broader range of vaccines for this population and highlighting that vaccine strategies may differ from those for the general population [<xref rid="B15-vaccines-13-00964" ref-type="bibr">15</xref>].</p><p>Although vaccinations are a priority for patients with cancer, available data highlighted the difficulty in achieving high coverage rates in this population. For example, despite a long-standing target of at least 75% influenza vaccination coverage among at-risk groups including cancer patients [<xref rid="B16-vaccines-13-00964" ref-type="bibr">16</xref>], evidence from various countries consistently showed substantially lower uptake in this population [<xref rid="B17-vaccines-13-00964" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00964" ref-type="bibr">18</xref>]. In this context, it is essential to recognize that patients should not be the sole actors in the vaccination decision. Patients with immunocompromising conditions seem to be particularly concerned about vaccine-related side-effects, trust in the effectiveness, and fear of deterioration of their underlying disease [<xref rid="B19-vaccines-13-00964" ref-type="bibr">19</xref>]. As a result, healthcare professionals (HCPs) play an important role in the patients&#8217; vaccination decision-making and collaboration between specialists and general practitioners is crucial [<xref rid="B20-vaccines-13-00964" ref-type="bibr">20</xref>]. Indeed, vaccination uptake is strongly influenced by HCP recommendations [<xref rid="B19-vaccines-13-00964" ref-type="bibr">19</xref>,<xref rid="B21-vaccines-13-00964" ref-type="bibr">21</xref>]. A recent review on the general population highlighted the value of behavioral strategies, such as tailored education, reminders, and direct communication, in addition to provider recommendations [<xref rid="B22-vaccines-13-00964" ref-type="bibr">22</xref>]. However, evidence on effective strategies in oncology settings remains limited and, in line with ASCO guidelines, vaccination should become a central component of cancer care [<xref rid="B15-vaccines-13-00964" ref-type="bibr">15</xref>].</p><p>Therefore, the present systematic review aimed to identify and synthesize existing interventions to improve vaccine uptake or reduce hesitancy among cancer patients and cancer survivors. In addition, this review sought to describe the efficacy of these strategies, providing an overview of the current evidence in this population.</p></sec><sec id="sec2-vaccines-13-00964"><title>2. Materials and Methods</title><p>This review was conducted according to the latest version of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [<xref rid="B23-vaccines-13-00964" ref-type="bibr">23</xref>]. The protocol of this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024511008). Preliminary findings from this review were presented as a poster at the 57th National Congress of the Italian Society of Hygiene, Preventive Medicine and Public Health (SItI) [<xref rid="B24-vaccines-13-00964" ref-type="bibr">24</xref>].</p><sec id="sec2dot1-vaccines-13-00964"><title>2.1. Eligibility Criteria</title><p>Methods and search strategy were planned in advance, after a preliminary literature analysis. The main review question was &#8220;Are there strategies to reduce vaccine hesitancy and/or improve vaccine adherence among cancer patients and/or cancer survivors? Are these strategies effective?&#8221; and the strategy was developed according to the PICO framework. About &#8220;Population&#8221;, all the studies about adult oncological patients were considered. We defined &#8220;adult&#8221; as any patient aged 18 years or older and &#8220;oncological patient&#8221; as any patient currently under treatment (chemotherapy, radiotherapy, and every other cancer therapy), newly diagnosed patients, patients currently in follow-up, and cancer survivors who had completed follow-up. Regarding &#8220;Intervention&#8221;, all the strategies or interventions that aimed to increase vaccine uptake or reduce vaccine hesitancy among cancer patients/survivors or enhance vaccine recommendations by HCPs were considered. Thus, the target of the intervention could be both patients and/or HCPs, as long as the ultimate broad aim of the intervention is to increase vaccine coverage among the oncological population. Considering &#8220;Comparison&#8221;, studies with any comparison were considered, including those without a control group. Lastly, for &#8220;Outcome&#8221;, studies with any primary outcome evaluating the efficacy of strategies to reduce the vaccine hesitancy and/or to improve vaccination adherence were considered; for instance: vaccine uptake/coverage in the oncological population, vaccine recommendations by HCPs, patients&#8217; willingness to get vaccinated, knowledge on vaccinations among oncological patients/survivors and/or HCPs.</p><p>We considered eligible only peer-reviewed research articles written in English, as this is the only language fully understood by all Authors in addition to their native language. We did not consider any restriction about country or publication year. In addition to the criteria defined by the PICO framework, we included any primary study with original data evaluating an intervention, regardless of design. Eligible study types included randomized controlled trials (RCTs), quasi-experimental studies (with or without control groups), case&#8211;control studies, and cohort studies. Research protocols, letters to the editor, and commentaries were excluded because they do not provide original data. According to this criterion, systematic and narrative reviews were excluded from data extraction. However, pertinent reviews were retained during the study selection to identify additional eligible primary studies in the bibliography.</p></sec><sec id="sec2dot2-vaccines-13-00964"><title>2.2. Information Sources and Search Strategy</title><p>We performed the primary search in three different databases (PubMed, Embase, and Scopus). PubMed and Embase were selected as they are considered essential databases for biomedical systematic reviews [<xref rid="B25-vaccines-13-00964" ref-type="bibr">25</xref>], while Scopus was added as a multidisciplinary source offering broad coverage and frequent use in evidence synthesis [<xref rid="B26-vaccines-13-00964" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00964" ref-type="bibr">27</xref>]. A predetermined search query was conducted on 24 November 2023, with adjustments applied to each database. Then, we set alerts to collect studies published by 31 December 2023. During a subsequent step, we noticed that the search query did not include some results of interest, so we decided to launch a second query with new keywords on 20 February 2024. The results of both queries and alerts were uploaded to the web application Rayyan of the Qatar Computing Research Institute [<xref rid="B28-vaccines-13-00964" ref-type="bibr">28</xref>].</p><p>The search strategy combined free-text terms and controlled vocabulary terms for three main concepts: vaccination (e.g., vaccine*, immuniz*, immunis*), cancer (e.g., cancer*, malignan*, tumor*, tumour*, neoplasm*), and vaccine hesitancy or uptake (e.g., hesit*, uptake*, coverage*, refus*). All the queries we used are shown in the <xref rid="app1-vaccines-13-00964" ref-type="app">Supplementary File (Supplementary File S1)</xref>.</p></sec><sec id="sec2dot3-vaccines-13-00964"><title>2.3. Selection Process</title><p>First, four Authors (G.L.M., A.B., S.C.C., F.G.) manually removed duplicates using Rayyan. The Authors proceeded to screen the title and abstract of all retrieved records. As a training, the Authors initially reviewed 5% of the papers. After a consensus-based discussion, the team proceeded to screen all the remaining titles and abstracts. Then, the Authors screened the full texts of the papers selected in the previous steps. Only after full-text selection, the reference lists of included studies were screened to identify additional relevant publications. The Authors also screened the reference lists of systematic reviews related to vaccines, cancer patients, and vaccination strategies, provided these reviews had been deemed relevant after full-text screening.</p><p>Every step of study selection was performed by at least two Authors independently and in duplicate and followed by a consensus-based discussion with the entire team to solve conflicts, except for the duplicate deletion.</p></sec><sec id="sec2dot4-vaccines-13-00964"><title>2.4. Data Collection Process and Data Items</title><p>Data extraction was performed using Microsoft Excel. The extracted data were: first author, year of publication, language, country; characteristics of the study, e.g., study design, sample size, presence of a control group, setting, length of the study and year of the study; characteristics of participants; characteristics of the intervention (and of the control group, if applicable), e.g., vaccine used, component of the intervention; outcome measures and results; presence of any declared conflicts of interest and funding sources; any other valuable comment. Following a discussion among all members of the research team, interventions were classified into categories and their main components were identified, to provide a narrative synthesis of the findings.</p><p>Every step of data extraction was performed by at least two Authors blinded to each other and followed by a consensus-based discussion with the entire team to solve conflicts.</p></sec><sec id="sec2dot5-vaccines-13-00964"><title>2.5. Study Risk of Bias Assessment</title><p>To assess the risk of bias of the RCTs, we used the Cochrane risk-of-bias tool for randomized trials (RoB 2) version 2 [<xref rid="B29-vaccines-13-00964" ref-type="bibr">29</xref>]. For the risk of bias in non-randomized studies, we used the revised Joanna Briggs Institute (JBI) critical appraisal tool [<xref rid="B30-vaccines-13-00964" ref-type="bibr">30</xref>]. At least two Authors independently rated each paper, and disagreements were solved by a consensus-based discussion with the entire team.</p></sec><sec id="sec2dot6-vaccines-13-00964"><title>2.6. Synthesis Methods</title><p>We conducted a narrative synthesis of the interventions. The synthesis focused on the types of strategies used and their reported primary outcomes and primary results. Due to heterogeneity in study designs, target populations, intervention components, and outcome measures no quantitative synthesis was performed. Along with a narrative synthesis, Summary of Findings tables were created to present the key characteristics and results of each included study.</p></sec><sec id="sec2dot7-vaccines-13-00964"><title>2.7. Effect Measures, Reporting Bias Assessment and Certainty Assessment</title><p>Due to the heterogeneity of interventions and as no quantitative synthesis was conducted, effect measures were not pooled across studies. Accordingly, no formal assessment of reporting bias was performed. We assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach [<xref rid="B31-vaccines-13-00964" ref-type="bibr">31</xref>]. The evaluation was performed by one reviewer and independently verified by a second reviewer. Given the heterogeneity of study designs, interventions, and outcomes, we restricted the assessment to the most frequently reported and relevant outcomes, as agreed upon by the review team after discussion. These included pneumococcal vaccination coverage (n = 10 studies), influenza vaccination coverage (n = 4), and COVID-19 vaccination coverage (n = 2).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00964"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00964"><title>3.1. Study Selection</title><p>We screened 10,927 not-duplicate records. <xref rid="vaccines-13-00964-f001" ref-type="fig">Figure 1</xref> summarizes the study selection flow. The complete flow diagram, including the two search queries separately, is available in the <xref rid="app1-vaccines-13-00964" ref-type="app">Supplementary Material (Supplementary Figure S1)</xref>. Once the full-text selection process was completed, 18 articles were considered eligible; two of these papers were reviews [<xref rid="B32-vaccines-13-00964" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00964" ref-type="bibr">33</xref>] (used for the backward citation chasing). Of the 16 remaining papers, two articles were by the same Author and described the same intervention and results [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00964" ref-type="bibr">35</xref>]. One of these papers [<xref rid="B35-vaccines-13-00964" ref-type="bibr">35</xref>] was a research letter and, in our results, we only considered the more comprehensive study [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>]. Thus, a total of 15 articles and unique interventions were included.</p><p>More than half of the studies (53.3%) declared no funding and only 2 studies (13.3%) did not report any information. Considering conflict of interests, 86.7% disclosed no conflicts and only 1 study (6.7%) did not have information about it. (<xref rid="app1-vaccines-13-00964" ref-type="app">Supplementary Table S1</xref>)</p></sec><sec id="sec3dot2-vaccines-13-00964"><title>3.2. Study Characteristics</title><p>All included studies were conducted between 2011 and 2022 (published between 2015 and 2023); 47% of studies were active in 2021. The studies occurred primarily in European/UK (40%) [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>] and North American (40%) [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>] settings; remaining studies were conducted in India, Israel, and Turkey [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. The most frequently used study design was pre-post (60%) [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>], while only two studies were RCTs [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. (<xref rid="vaccines-13-00964-t001" ref-type="table">Table 1</xref>) Some form of control group (usual care) was present in 33.3% of the studies [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] (<xref rid="app1-vaccines-13-00964" ref-type="app">Table S1</xref>).</p><p>The studies varied in length from the shortest (17 days [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>]) to the longest (28 months [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]), with 60% of studies lasting at least 12 months [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. Most interventions were directly targeted to patients (40%) [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>], 33.3% were targeted to both HCPs and patients [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>], and 26.7% only HCPs [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]. The number of participants in the interventions ranged from 10 HCPs [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>] to 3603 patients [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]; however, 26.7% of the studies did not report participant numbers. More than half of the studies (60%) did not consider only a specific type of cancer. Three studies (18.8%) focused on onco-hematologic diseases [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>], 2 studies (12.5%) on gynecologic cancers [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>], 2 studies on gastroenterological cancers (12.5%) [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>], and 1 on lung cancer (6.3%) [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>]. Only 1 study [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>] also considered pediatric patients. Most interventions concerned vaccinations against flu and pneumococcal disease (26.7%) [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>], vaccinations against pneumococcal disease (26.7%) [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] or Coronavirus Disease 2019 (COVID-19) (26.7%) [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]. Only one study (6.7%) targeted herpes zoster and hepatitis b in addition to flu and pneumococcal disease [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>]. In one study (6.7%) [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>], although the evaluation was focused on flu and pneumococcal vaccinations, the intervention also addressed diphtheria-tetanus-poliomyelitis, hepatitis b, and papillomavirus (HPV) vaccinations.</p><p>A large proportion of the interventions had multiple components (60%) [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. Only 2 interventions (13.3%) were delivered entirely online [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>]. The interventions were grouped into three main categories: educational materials and campaigns (included in 46.7% of interventions [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]), reminders (in 40% [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]), and patient counselling (in 33.3% [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]). Among additional components, the development of specific vaccination guidelines or protocols was a recurring element, implemented in two interventions [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]. Most studies (86.7%, n = 13) assessed patient vaccination rates as the primary outcome [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>], even when the intervention was primarily directed at HCPs. Among these, 66.7% (n = 10) reported statistically significant improvements in vaccination rates. Only three studies (20%) [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] evaluated other types of outcomes, such as vaccine intention, and changes in beliefs, attitudes, or knowledge. Information about the components is reported in <xref rid="vaccines-13-00964-t002" ref-type="table">Table 2</xref>, while the information about primary outcomes and results is presented in <xref rid="vaccines-13-00964-t003" ref-type="table">Table 3</xref>.</p><p>In conclusion, the included studies were highly heterogeneous, precluding quantitative synthesis. This heterogeneity was largely driven by substantial differences in intervention composition and target populations. For instance, focusing on the three most frequently reported outcomes, only in two cases did the studies with pneumococcal vaccination coverage as the primary outcome (n = 10) involve interventions that could be classified into similar categories; the remaining cases differed in their components. For influenza (n = 4) and COVID-19 vaccination coverage (n = 2), interventions were entirely distinct in composition. Differences in delivery modes, target groups, and outcome measures further limited comparability and made pooling of results infeasible.</p></sec><sec id="sec3dot3-vaccines-13-00964"><title>3.3. Results Synthesis</title><sec id="sec3dot3dot1-vaccines-13-00964"><title>3.3.1. Educational Materials and Campaigns</title><p>Educational materials and campaigns were the most frequent component, being present in 7 interventions (46.7%) [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. Education was targeted at patients (n = 3) [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>], HCPs (n = 2) [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>], or both HCPs and patients (n = 2) [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]. The majority of interventions included other components in addition to education (n = 5) [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>].</p><p>In 5 interventions, it was the sole component [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>] or the main component [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]. All these studies had a quasi-experimental design. The two studies that included exclusively an educational component were both focused on COVID-19 vaccination and delivered online in different formats. One was an educational webinar targeting both patients and HCPs aimed at improving knowledge about COVID-19 vaccination and reducing hesitancy [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>], while the other was an interactive web tool offering individualized information on vaccine benefits and risks for patients [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>]. Although both interventions reported improvements in vaccine intention, neither study conducted statistical analyses to confirm significance. However, Kelkar et al. [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>] did report a statistically significant change in beliefs and perspectives on COVID-19 vaccines.</p><p>Among the multi-component interventions in which education was the main component [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>,<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>,<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>], results were mixed. Overall, the training aimed to update HCPs on vaccinations and encourage them to actively recommend vaccines to patients. When HCP education was combined with the recruitment of an advanced practice nurse practitioner (APRN) to act as a safety net, reviewing patients&#8217; vaccination status and prescribing vaccines when oncologists had not, a significant increase in patient vaccination coverage was observed [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]. Notably, the APRN&#8217;s involvement was not part of the original design but was introduced after an interim review, as oncologists were not addressing vaccination despite training [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]. When HCP training sessions were accompanied by the development of a vaccination protocol validated by infectious disease specialists [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>], no significant changes in coverage were observed. The combination of HCP education, patient education (i.e., information brochures), pre-printed prescriptions to improve the ease of prescribing vaccines for physicians, and organizational changes such as an in-house vaccination program [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>] led to large increases in coverage although no inferential analyses were conducted by the Authors.</p></sec><sec id="sec3dot3dot2-vaccines-13-00964"><title>3.3.2. Reminders</title><p>Reminders of any kind (e.g., text messages, telephone calls, personalized letters, pop-up alerts) were a component in 6 interventions (40%) [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]. Reminders were targeted at patients (n = 1) [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>], HCPs (n = 2) [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>], or both HCPs and patients (n = 3) [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]. Most interventions included other components beyond reminders (n = 5) [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>].</p><p>In 5 interventions, reminders were the only component [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>] or the main component [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]. Most studies had a quasi-experimental design, while one was a natural experiment [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]. Considering patient reminders, most interventions (n = 3) included letters, text messages, phone calls, or emails [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>], while one involved posters [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]. As for HCP reminders, an alert in the Electronic Medical Record (EMR) was the most frequent action (n = 3) [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>], while also physical cards or charts were used in two cases [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]. All these interventions produced statistically significant improvements in vaccination rates.</p><p>The single-component intervention [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>] could be classified as both an HCP reminder and a form of protocol provision. It consisted of a card listing vaccination recommendations for cancer patients, specifically designed to remind and guide general practitioners (GPs). Patients acted as intermediaries, receiving the card from their oncologist or hematologist and delivering it to their GP. Vaccination coverage significantly increased more in the intervention group (+21.5pp) than in the control group (&#8722;5.8pp).</p><p>Three interventions included reminders both for patients and for HCPs [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>,<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]. In the intervention by Church et al. [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>], providers from a virtual clinic entered vaccine orders in the EMR as reminders for HCPs, documented the rationale, and involved the primary care team. Moreover, they sent letters as reminders to patients. To isolate the effect of the virtual clinic from a prior national clinical reminder, time-to-vaccination curves were compared, showing a significant difference in favor of the virtual clinic. In the work by Grivas et al. [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>], multiple HCP reminders were implemented, including &#8220;screen pop-ups&#8221; in the EMR, laminated reminders placed in the paper chart, and visual cues (e.g., stickers) to encourage discussion and vaccine ordering. Reminders for patients were posted in clinic areas near elevators, alongside educational materials shared via the institution&#8217;s website and social media. The intervention led to a significant increase in vaccination. Shapiro et al. [<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>] described an intervention during which HCPs received EMR alerts, prompting vaccine prescriptions, and patients were actively reminded through their digital health record, text messages, and emails every six months. Additionally, preapproval requirements for PCV13 were waived. Vaccination rates significantly increased for both PCV13 and PPSV23.</p><p>Lastly, in the intervention by Narinx et al. [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>], patients received repeated personalized reminders via letters, phone calls, and messages. In addition, the intervention also included counselling during hospital visits and direct access to healthcare professionals for questions. The vaccination coverage in the intervention group was significantly higher than in the general population.</p><p>It is also worth noting the sixth intervention that included reminders, although not as a primary component [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]. This was a multi-component intervention targeting HCPs, with its core element being the development of vaccination guidelines. These were disseminated to hospital practitioners via email and internal presentations, and to local primary care physicians via email. Additional components included summary posters for HCPs placed in clinic rooms and a letter for patients to deliver to their primary care providers. Pneumococcal vaccination rates increased significantly following the intervention, whereas influenza vaccination rates (although consistently around 70%) did not change significantly.</p></sec><sec id="sec3dot3dot3-vaccines-13-00964"><title>3.3.3. Patient Counselling</title><p>Patient counselling was included in 5 interventions (33.3%) [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. Only two interventions [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] included additional components. Vaccination counselling was performed by physicians (n = 2) (infectious diseases specialist [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>], oncologist [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]), pharmacists (n = 2) [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>], and unspecified HCPs during hospital visits (n = 1) [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>].</p><p>In 4 interventions, patient counselling was the only component [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>] or the main component [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]. Two studies had a quasi-experimental design [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>,<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]: one of them showed a significant improvement in vaccination rates [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>], while the other described a post-intervention analysis without inferential statistics [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]. Two were RCTs [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] and both reported a significant improvement in vaccination rates. Considering the single-component interventions, Sitte et al. [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>] implemented consultation with a senior infectious diseases specialist. During the visit, the timing of live attenuated vaccines and the updating of various vaccinations (including diphtheria&#8211;tetanus&#8211;poliomyelitis, HBV, influenza, and pneumococcal vaccines) were discussed, leading to a significant increase in pneumococcal vaccination rates. In the study by Ganju et al. [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>], patients were actively counseled by treating oncologists regarding the available COVID-19 vaccines during clinic visits or hospital admissions. At least one dose of COVID-19 vaccine was administered to 86% of the patients and 67% received both doses. Nipp et al. [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>] evaluated an intervention based on a pharmacist&#8217;s visit. The pharmacist met with patients and collected a detailed vaccination history, recommended guideline-indicated vaccinations, and communicated these recommendations to the oncology team. Patients in the intervention had higher rates of newly received vaccinations for pneumonia and influenza compared with those receiving usual care.</p><p>Last, Ozdemir et al. [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] evaluated a pharmacist-led intervention. The intervention group received counselling about immunization, pneumococcal disease and vaccines, and misconceptions about vaccines; they also received educational materials on these topics. The pneumococcal vaccine was recommended according to guidelines and patients in the intervention group were followed up by phone calls 3 months after the intervention. The intervention group achieved significantly higher vaccination rates and demonstrated greater knowledge and more favorable attitudes toward vaccination.</p></sec></sec><sec id="sec3dot4-vaccines-13-00964"><title>3.4. Risk of Bias in Studies and Certainty of Evidence</title><p>Among quasi-experimental and natural experimental studies (n = 13), two frequent sources of high risk of bias were identified: the absence of an independent control group (present in only 23.1% of studies; [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>,<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>,<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]) and the lack of repeated outcome measurements before and after the intervention (reported in only 7.6% [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]) (<xref rid="app1-vaccines-13-00964" ref-type="app">Table S2</xref>). As for the two RCTs [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>,<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>], they were judged at low risk of bias for missing outcome data, measurement of the outcome, and selection of the reported result. Both RCTs were at high risk of bias for the randomization process domain. One study [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>] was at low risk of bias regarding deviations from intended interventions, while the other [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>] raised some concerns in this domain. Overall, both RCTs were rated as having a high risk of bias (<xref rid="app1-vaccines-13-00964" ref-type="app">Figure S2</xref>).</p><p>Due to the substantial variation across interventions, in most cases the certainty of the evidence using the GRADE assessment was based on a single study. Only in two instances (both concerning the primary outcome of pneumococcal vaccination coverage) two papers reporting interventions with similar components were considered together in the assessment. Across all three outcomes, the certainty of evidence was rated for each intervention as very low. This was predominantly due to risk of bias and imprecision (<xref rid="app1-vaccines-13-00964" ref-type="app">Table S3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00964"><title>4. Discussion</title><p>This systematic review identified strategies to improve vaccine uptake or reduce vaccine hesitancy among cancer patients. Despite heterogeneity in settings, populations, and intervention designs, several key themes emerged. Interventions fell into three main categories: education, reminders, and counselling.</p><p>Educational materials and campaigns were the most frequently used components across interventions. These strategies targeted either HCPs, patients, or both. Among multi-component interventions where HCP education was the primary element, results were mixed. Interestingly, in one study [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>], provider training combined with the subsequent addition of an APRN to review vaccination status and prescribe vaccines led to a significant increase in coverage. The APRN was introduced after it became clear that oncologists were not addressing vaccination despite prior training. This underscored a critical limitation of education-only interventions: knowledge alone may not translate into action without structural or workflow support. Indeed, when HCP education was paired solely with the development and dissemination of a vaccination protocol [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>], no statistically significant improvements in vaccination rates were observed. This was the only study in the entire review where statistical testing was performed and failed to show a benefit. In contrast, when HCP education was combined with patient-directed education, it also led to positive outcomes [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]. These findings suggest that educating oncology professionals is a valuable foundation but must be integrated into broader strategies that address other barriers. Simply providing information or guidelines may not be enough to overcome competing priorities, uncertainty about clinical roles, or lack of time. These findings may also reflect that changing human health-related behavior is difficult and takes time [<xref rid="B50-vaccines-13-00964" ref-type="bibr">50</xref>]. Ensuring that someone within the care team is explicitly tasked with reviewing vaccination status and initiating vaccination, such as an APRN, may thus increase continuity of care.</p><p>Reminders represented another key component and were consistently associated with significant improvements in vaccination uptake. Consistently, in other context, reminder-based interventions have proven effective in increase vaccine adherence among at-risk populations, especially when integrated into multi-modal strategies [<xref rid="B51-vaccines-13-00964" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-13-00964" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-13-00964" ref-type="bibr">53</xref>]. These interventions employed a variety of formats depending on the target: patient-directed reminders most commonly involved letters, text messages, phone calls, or emails. For HCPs, reminders were often embedded into clinical workflows through EMR alerts. These results aligned with findings in other populations, such as the study of Morgan et al. [<xref rid="B54-vaccines-13-00964" ref-type="bibr">54</xref>], who found increased vaccine uptake in prenatal care, and the one of Ruffin et al. [<xref rid="B55-vaccines-13-00964" ref-type="bibr">55</xref>], who found significant increases in HPV vaccine uptake after the introduction of a reminder system. Moreover, our review highlighted how reminders can be effectively used not only within hospital systems but also to engage primary care providers and GPs, who, despite playing a key role in delivering vaccines to cancer patients, especially in outpatient and survivorship settings, are often neglected in intervention planning and discussions focused mainly on specialists. The importance of the primary care physician is also evident in other studies, such as the study by Monier et al. targeting cancer patients, in which vaccine information provided by the primary care physician was a factor significantly associated with higher vaccination rates [<xref rid="B56-vaccines-13-00964" ref-type="bibr">56</xref>].</p><p>Patient counselling was used in one-third of interventions and was consistently associated with improved vaccination uptake. In the two RCTs, counselling interventions were delivered by pharmacists, providing the most robust evidence. Our results are consistent with prior literature: the efficacy of counselling and recommendations has already been proved in other populations [<xref rid="B57-vaccines-13-00964" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-13-00964" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-13-00964" ref-type="bibr">59</xref>]. Counselling is especially important for cancer patients, as previous studies have shown that oncologist recommendations strongly influence vaccine acceptance [<xref rid="B21-vaccines-13-00964" ref-type="bibr">21</xref>,<xref rid="B60-vaccines-13-00964" ref-type="bibr">60</xref>]. However, our review suggested that effective counselling can also be delivered by other professionals, such as pharmacists or infectious disease specialists, broadening the scope of who can successfully support vaccine decision-making in oncology care. Integrating patient counselling into oncology workflows, especially via pharmacists, emerged as a promising model. Pharmacists are accessible, knowledgeable about medication, and capable of reinforcing provider recommendations without adding to oncologists&#8217; workload. This approach may be particularly valuable in settings where oncologists have limited time or competing priorities. Moreover, qualitative research supported the view that pharmacists are well suited to this role, offering trusted, patient-centered dialogue that can clarify concerns and provide vaccine recommendations [<xref rid="B61-vaccines-13-00964" ref-type="bibr">61</xref>]. Lastly, according to research beyond cancer care, pharmacist&#8217;s involvement in immunization programs showed positive effects not only in increasing vaccine uptake but also in other outcomes such as patient satisfaction [<xref rid="B62-vaccines-13-00964" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-13-00964" ref-type="bibr">63</xref>].</p><p>Furthermore, additional important considerations emerged. The most commonly targeted vaccines were those against influenza, pneumococcal disease, and COVID-19. However, these represent only a portion of the immunizations currently recommended for cancer patients. According to the ASCO guidelines published in 2024 [<xref rid="B15-vaccines-13-00964" ref-type="bibr">15</xref>], additional vaccines, e.g., those against herpes zoster, respiratory syncytial virus (RSV), hepatitis B, and HPV, should also be considered, depending on patient eligibility. The limited focus on a narrow set of vaccines in the included interventions likely reflected the period in which the studies were conducted, prior to the broader recommendations outlined by ASCO. This highlights an opportunity for future research to explore interventions addressing a wider range of vaccines and to assess the feasibility of multi-vaccine delivery strategies within oncology care. It is also worth noting that none of the included studies tested innovative interventions targeting HCPs, such as mobile apps, serious games, or role-play simulations, approaches that have shown promise in other HCP subgroups [<xref rid="B64-vaccines-13-00964" ref-type="bibr">64</xref>]. Exploring these strategies in oncology settings could offer new ways to engage providers. Lastly, the importance of multi-component interventions has been well supported by existing literature, [<xref rid="B51-vaccines-13-00964" ref-type="bibr">51</xref>,<xref rid="B65-vaccines-13-00964" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00964" ref-type="bibr">66</xref>]. These studies also emphasized that tailoring interventions to the specific characteristics and needs of the target population may further enhance their impact [<xref rid="B51-vaccines-13-00964" ref-type="bibr">51</xref>,<xref rid="B65-vaccines-13-00964" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00964" ref-type="bibr">66</xref>]. This supports the need for oncology-focused strategies that combine multiple actions and address the unique needs of cancer patients.</p><p>Several limitations should be considered when interpreting the results of this review. First of all, there was a wide heterogeneity among the included studies, limiting possible quantitative analyses. The overall methodological quality of the studies was low: most were quasi-experimental, with few including independent control groups or pre-post comparisons. Only two studies were randomized controlled trials, and both were rated at high risk of bias, particularly in the randomization process. Indeed, considering the overall quality of evidence, our findings highlighted a very low quality. This does not necessarily indicate lack of efficacy but rather reflects the limited robustness, heterogeneity, and methodological weaknesses of the available studies. The outcomes were mostly limited to vaccination coverage, the specific contribution of each component within multi-component interventions could not be determined, and the included studies generally did not explore whether intervention efficacy varied according to patient characteristics. Moreover, long-term effects and sustainability of the interventions remained largely unexplored. Another limitation concerned the generalizability of findings. The majority of studies were conducted in Europe and North America, with limited representation of low- and middle-income settings. Considering our Methods, we acknowledge that limiting the search to three databases and including only papers written in English may have led to the exclusion of some relevant records.</p><p>In conclusion, future studies should prioritize the development and evaluation of rigorously designed interventions, ideally through high-quality randomized controlled trials, to strengthen evidence in this field. Research should expand beyond influenza, pneumococcal disease, and COVID-19 vaccines and particular attention should be given to multi-component, oncology-tailored approaches that integrate educational, reminder-based, and counselling strategies, while exploring innovative digital solutions to engage both HCPs and patients. To effectively integrate the roles of oncologists, pharmacists, infectious disease specialists, and primary care providers, future research should also investigate resource needs, feasibility, and barriers, which are often highly context-specific. Moreover, studies should assess the differential impact of interventions across diverse patient subgroups, e.g., by cancer stage, and should evaluate long-term sustainability and cost-effectiveness. Another important direction is to explore strategies to protect cancer patients from misinformation and false rumors spread by anti-vaccination movements. Finally, extending research to low- and middle-income countries will be essential to ensure equitable access to vaccination and to generate context-specific evidence relevant to different healthcare systems.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00964"><title>5. Conclusions</title><p>This systematic review highlighted a range of strategies mainly aimed at improving vaccine uptake among cancer patients. Interventions fell into three main categories (education, reminders, and counselling) all of which showed potential, particularly when combined. Educational initiatives targeting oncology professionals were common but appeared most effective when paired with other changes, such as designating a team member to oversee vaccinations or including patient education. Reminders consistently improved coverage and were also effective when they included primary care providers, a group often overlooked despite their central role in vaccine delivery. Patient counselling also showed positive outcomes and may be successfully delivered by a range of professionals, including pharmacists. However, most interventions focused on only a few vaccines and there were issues in the generalizability of results and in the methodology of the studies. Future studies should prioritize rigorous designs and the use of shared, standardized outcome measures to enhance comparability and evaluation.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00964"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/vaccines13090964/s1">https://www.mdpi.com/article/10.3390/vaccines13090964/s1</uri>, Supplementary File S1: Supplementary Methods. Search terms; Figure S1: Full flow diagram; Figure S2: Rob2 Evaluation; Table S1: Additional characteristics of the included studies; Table S2: Risk of bias of the quasi-experimental and natural experimental studies; Table S3: Quality of evidence evaluation. Ref. [<xref rid="B67-vaccines-13-00964" ref-type="bibr">67</xref>] is cited in <xref rid="app1-vaccines-13-00964" ref-type="app">Supplementary Materials</xref>.</p><supplementary-material id="vaccines-13-00964-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vaccines-13-00964-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, G.L.M., G.S., R.S. and F.B.; methodology, G.L.M., G.S., R.S. and F.B.; investigation, G.L.M., F.G., S.C.C. and A.B.; data curation, G.L.M., F.G., S.C.C. and A.B.; writing&#8212;original draft preparation, G.L.M., F.G., S.C.C. and A.B.; writing&#8212;review and editing, G.L.M., G.S., R.S. and F.B.; visualization, G.L.M., F.G., S.C.C. and A.B.; supervision, G.L.M., R.S. and F.B.; project administration, G.L.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">APRN</td><td align="left" valign="middle" rowspan="1" colspan="1">Advanced Practice Nurse Practitioner</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASCO</td><td align="left" valign="middle" rowspan="1" colspan="1">American Society of Clinical Oncology</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic Medical Record</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GP</td><td align="left" valign="middle" rowspan="1" colspan="1">General Practitioner </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCP</td><td align="left" valign="middle" rowspan="1" colspan="1">Healthcare Professional</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PICO</td><td align="left" valign="middle" rowspan="1" colspan="1">Population, Intervention, Comparison, Outcome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PRISMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Preferred Reporting Items for Systematic reviews and Meta-Analyses</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PROSPERO</td><td align="left" valign="middle" rowspan="1" colspan="1">International Prospective Register of Systematic Reviews</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RCT</td><td align="left" valign="middle" rowspan="1" colspan="1">Randomized Controlled Trial</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-13-00964"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>International Agency for Research on Cancer Cancer Today</collab></person-group><article-title>Absolute Numbers, Incidence, Both Sexes, in 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://gco.iarc.fr/today/en/dataviz/pie?mode=population&amp;group_populations=0&amp;types=0&amp;populations=900" ext-link-type="uri">https://gco.iarc.fr/today/en/dataviz/pie?mode=population&amp;group_populations=0&amp;types=0&amp;populations=900</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-30">(accessed on 30 July 2025)</date-in-citation></element-citation></ref><ref id="B2-vaccines-13-00964"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okoli</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>O.L.T.</given-names></name><name name-style="western"><surname>Abdulwahid</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neilson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abou-Setta</surname><given-names>A.M.</given-names></name></person-group><article-title>Seasonal Influenza Vaccination among Cancer Patients: A Systematic Review and Meta-Analysis of the Determinants</article-title><source>Curr. Probl. Cancer</source><year>2021</year><volume>45</volume><fpage>100646</fpage><pub-id pub-id-type="doi">10.1016/j.currproblcancer.2020.100646</pub-id><pub-id pub-id-type="pmid">32917396</pub-id></element-citation></ref><ref id="B3-vaccines-13-00964"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunisaki</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Janoff</surname><given-names>E.N.</given-names></name></person-group><article-title>Influenza in Immunosuppressed Populations: A Review of Infection Frequency, Morbidity, Mortality, and Vaccine Responses</article-title><source>Lancet Infect. Dis.</source><year>2009</year><volume>9</volume><fpage>493</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(09)70175-6</pub-id><pub-id pub-id-type="pmid">19628174</pub-id><pub-id pub-id-type="pmcid">PMC2775097</pub-id></element-citation></ref><ref id="B4-vaccines-13-00964"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name></person-group><article-title>Fatal Infections Among Cancer Patients: A Population-Based Study in the United States</article-title><source>Infect. Dis. Ther.</source><year>2021</year><volume>10</volume><fpage>871</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00433-7</pub-id><pub-id pub-id-type="pmid">33761114</pub-id><pub-id pub-id-type="pmcid">PMC8116465</pub-id></element-citation></ref><ref id="B5-vaccines-13-00964"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elhadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khaled</surname><given-names>A.</given-names></name><name name-style="western"><surname>Msherghi</surname><given-names>A.</given-names></name></person-group><article-title>Infectious Diseases as a Cause of Death among Cancer Patients: A Trend Analysis and Population-Based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results Database</article-title><source>Infect. Agent. Cancer</source><year>2021</year><volume>16</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s13027-021-00413-z</pub-id><pub-id pub-id-type="pmid">34972537</pub-id><pub-id pub-id-type="pmcid">PMC8719405</pub-id></element-citation></ref><ref id="B6-vaccines-13-00964"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homsi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Panta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lagman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Longworth</surname><given-names>D.L.</given-names></name></person-group><article-title>Infectious Complications of Advanced Cancer</article-title><source>Support. Care Cancer</source><year>2000</year><volume>8</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1007/s005200000143</pub-id><pub-id pub-id-type="pmid">11094994</pub-id></element-citation></ref><ref id="B7-vaccines-13-00964"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mariette</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bachelez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Belot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonnotte</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hachulla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lahfa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lortholary</surname><given-names>O.</given-names></name><name name-style="western"><surname>Loulergue</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Vaccination Recommendations for the Adult Immunosuppressed Patient: A Systematic Review and Comprehensive Field Synopsis</article-title><source>J. Autoimmun.</source><year>2017</year><volume>80</volume><fpage>10</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2017.03.011</pub-id><pub-id pub-id-type="pmid">28381345</pub-id></element-citation></ref><ref id="B8-vaccines-13-00964"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkwood</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bruinooge</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kaltenbaugh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gralow</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Garrett-Mayer</surname><given-names>E.</given-names></name></person-group><article-title>Differential Survival Among Patients With Cancer by COVID-19 Vaccination Status: An Analysis of the ASCO COVID-19 Registry</article-title><source>JCO Oncol. Adv.</source><year>2024</year><volume>1</volume><fpage>e2400034</fpage><pub-id pub-id-type="doi">10.1200/OA-24-00034</pub-id></element-citation></ref><ref id="B9-vaccines-13-00964"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bersanelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verzoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cortellini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calvetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ermacora</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Napoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Catino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guadalupi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guaitoli</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Impact of Influenza Vaccination on Survival of Patients with Advanced Cancer Receiving Immune Checkpoint Inhibitors (INVIDIa-2): Final Results of the Multicentre, Prospective, Observational Study</article-title><source>eClinicalMedicine</source><year>2023</year><volume>61</volume><fpage>102044</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102044</pub-id><pub-id pub-id-type="pmid">37434748</pub-id><pub-id pub-id-type="pmcid">PMC10331809</pub-id></element-citation></ref><ref id="B10-vaccines-13-00964"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>W.</given-names></name></person-group><article-title>Impact of 23-valent Pneumococcal Polysaccharide Vaccination on the Frequency of Pneumonia-related Hospitalization and Survival in Elderly Patients with Prostate Cancer: A Seven-year Nationwide Matched Cohort Study</article-title><source>Cancer</source><year>2021</year><volume>127</volume><fpage>124</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1002/cncr.33203</pub-id><pub-id pub-id-type="pmid">32997342</pub-id></element-citation></ref><ref id="B11-vaccines-13-00964"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>A.</given-names></name><name name-style="western"><surname>La</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Carrico</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lorenc</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Poston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>C.F.</given-names></name></person-group><article-title>Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States</article-title><source>Pharmacoecon. Open</source><year>2023</year><volume>7</volume><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1007/s41669-023-00438-7</pub-id><pub-id pub-id-type="pmid">37917310</pub-id><pub-id pub-id-type="pmcid">PMC10721768</pub-id></element-citation></ref><ref id="B12-vaccines-13-00964"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>B.-H.</given-names></name><name name-style="western"><surname>Stoecker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Link-Gelles</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.R.</given-names></name></person-group><article-title>Cost-Effectiveness of Administering 13-Valent Pneumococcal Conjugate Vaccine in Addition to 23-Valent Pneumococcal Polysaccharide Vaccine to Adults with Immunocompromising Conditions</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>6011</fpage><lpage>6021</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.024</pub-id><pub-id pub-id-type="pmid">24148572</pub-id></element-citation></ref><ref id="B13-vaccines-13-00964"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avritscher</surname><given-names>E.B.C.</given-names></name><name name-style="western"><surname>Cooksley</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Geraci</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bekele</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Rolston</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Elting</surname><given-names>L.S.</given-names></name></person-group><article-title>Cost-effectiveness of Influenza Vaccination in Working-age Cancer Patients</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>2357</fpage><lpage>2364</lpage><pub-id pub-id-type="doi">10.1002/cncr.22670</pub-id><pub-id pub-id-type="pmid">17457827</pub-id></element-citation></ref><ref id="B14-vaccines-13-00964"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beckerich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cordonnier</surname><given-names>C.</given-names></name></person-group><article-title>Immunization in Cancer Patients: Where We Stand</article-title><source>Pharmacol. Res.</source><year>2015</year><volume>92</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2014.10.002</pub-id><pub-id pub-id-type="pmid">25461457</pub-id></element-citation></ref><ref id="B15-vaccines-13-00964"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamboj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bohlke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baptiste</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dunleavy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fueger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kelkar</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Law</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>LeFebvre</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Ljungman</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Vaccination of Adults With Cancer: ASCO Guideline</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>1699</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1200/JCO.24.00032</pub-id><pub-id pub-id-type="pmid">38498792</pub-id><pub-id pub-id-type="pmcid">PMC11095883</pub-id></element-citation></ref><ref id="B16-vaccines-13-00964"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Commission of the European Communities</collab></person-group><source>Council Recommendation on Seasonal Influenza Vaccination</source><publisher-name>Commission of the European Communities</publisher-name><publisher-loc>Brussels, Belgium</publisher-loc><year>2009</year></element-citation></ref><ref id="B17-vaccines-13-00964"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amdisen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abildgaard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Benn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>R&#248;rth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cronin-Fenton</surname><given-names>D.</given-names></name><name name-style="western"><surname>S&#248;rup</surname><given-names>S.</given-names></name></person-group><article-title>The Coverage of Influenza Vaccination and Predictors of Influenza Non-Vaccination in Danish Cancer Patients: A Nationwide Register-Based Cohort Study</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>1690</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.02.009</pub-id><pub-id pub-id-type="pmid">38350769</pub-id></element-citation></ref><ref id="B18-vaccines-13-00964"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ellingson</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Bednarczyk</surname><given-names>R.A.</given-names></name></person-group><article-title>Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey</article-title><source>Open Forum Infect. Dis.</source><year>2021</year><volume>8</volume><fpage>ofab198</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofab198</pub-id><pub-id pub-id-type="pmid">34322565</pub-id><pub-id pub-id-type="pmcid">PMC8312520</pub-id></element-citation></ref><ref id="B19-vaccines-13-00964"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doornekamp</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Gorp</surname><given-names>E.</given-names></name><name name-style="western"><surname>Voeten</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goeijenbier</surname><given-names>M.</given-names></name></person-group><article-title>Determinants of Vaccination Uptake in Risk Populations: A Comprehensive Literature Review</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030480</pub-id><pub-id pub-id-type="pmid">32867126</pub-id><pub-id pub-id-type="pmcid">PMC7563537</pub-id></element-citation></ref><ref id="B20-vaccines-13-00964"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doherty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt-Ott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Stanberry</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name></person-group><article-title>Vaccination of Special Populations: Protecting the Vulnerable</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>6681</fpage><lpage>6690</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.015</pub-id><pub-id pub-id-type="pmid">27876197</pub-id></element-citation></ref><ref id="B21-vaccines-13-00964"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Joung</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Eom</surname><given-names>B.W.</given-names></name><etal/></person-group><article-title>Cancer Patients&#8217; Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>3883</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13153883</pub-id><pub-id pub-id-type="pmid">34359783</pub-id><pub-id pub-id-type="pmcid">PMC8345425</pub-id></element-citation></ref><ref id="B22-vaccines-13-00964"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shafiq</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elharake</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>James</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nyhan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Paintsil</surname><given-names>E.</given-names></name><name name-style="western"><surname>Melchinger</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Team</surname><given-names>Y.B.I.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>F.A.</given-names></name><etal/></person-group><article-title>Behavioral Interventions for Vaccination Uptake: A Systematic Review and Meta-Analysis</article-title><source>Health Policy</source><year>2023</year><volume>137</volume><fpage>104894</fpage><pub-id pub-id-type="doi">10.1016/j.healthpol.2023.104894</pub-id><pub-id pub-id-type="pmid">37714082</pub-id><pub-id pub-id-type="pmcid">PMC10885629</pub-id></element-citation></ref><ref id="B23-vaccines-13-00964"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref><ref id="B24-vaccines-13-00964"><label>24.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Calabrese</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lo Moro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Basile</surname><given-names>A.</given-names></name><name name-style="western"><surname>Golzio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scaioli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Siliquini</surname><given-names>R.</given-names></name></person-group><article-title>Strategies to Improve Vaccine Adherence in Adult Oncology Patients: A Systematic Review</article-title><source>Proceedings of the Atti 57&#176; Congresso Nazionale Societ&#224; Italiana Igiene, Medicina Preventiva e Sanit&#224; Pubblica (SItI)</source><conf-loc>Palermo, Italy</conf-loc><conf-date>23&#8211;26 October 2024</conf-date><fpage>E490</fpage></element-citation></ref><ref id="B25-vaccines-13-00964"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Glanville</surname><given-names>J.</given-names></name><name name-style="western"><surname>Briscoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Featherstone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Littlewood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Metzendorf</surname><given-names>M.-I.</given-names></name><name name-style="western"><surname>Noel-Storr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paynter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rader</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Chapter 4: Searching for and Selecting Studies</article-title><source>Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1 Cochrane</source><person-group person-group-type="editor"><name name-style="western"><surname>Higgins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cumpston</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Page</surname><given-names>M.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>V.</given-names></name></person-group><publisher-name>John Wiley &amp; Sons</publisher-name><publisher-loc>Chichester, UK</publisher-loc><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04#section-4-7" ext-link-type="uri">https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04#section-4-7</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-03">(accessed on 3 September 2025)</date-in-citation></element-citation></ref><ref id="B26-vaccines-13-00964"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gusenbauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haddaway</surname><given-names>N.R.</given-names></name></person-group><article-title>Which Academic Search Systems Are Suitable for Systematic Reviews or Meta-analyses? Evaluating Retrieval Qualities of Google Scholar, PubMed, and 26 Other Resources</article-title><source>Res. Synth. Methods</source><year>2020</year><volume>11</volume><fpage>181</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1002/jrsm.1378</pub-id><pub-id pub-id-type="pmid">31614060</pub-id><pub-id pub-id-type="pmcid">PMC7079055</pub-id></element-citation></ref><ref id="B27-vaccines-13-00964"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pranckut&#279;</surname><given-names>R.</given-names></name></person-group><article-title>Web of Science (WoS) and Scopus: The Titans of Bibliographic Information in Today&#8217;s Academic World</article-title><source>Publications</source><year>2021</year><volume>9</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/publications9010012</pub-id></element-citation></ref><ref id="B28-vaccines-13-00964"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouzzani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hammady</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fedorowicz</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Elmagarmid</surname><given-names>A.</given-names></name></person-group><article-title>Rayyan&#8212;A Web and Mobile App for Systematic Reviews</article-title><source>Syst. Rev.</source><year>2016</year><volume>5</volume><fpage>210</fpage><pub-id pub-id-type="doi">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmid">27919275</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id></element-citation></ref><ref id="B29-vaccines-13-00964"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>J.A.C.</given-names></name><name name-style="western"><surname>Savovi&#263;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Page</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Blencowe</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cates</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials</article-title><source>BMJ</source><year>2019</year><volume>366</volume><fpage>l4898</fpage><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id></element-citation></ref><ref id="B30-vaccines-13-00964"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aromataris</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Leonardi-Bee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hasanoff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klugar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tufanaru</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moola</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The Revised JBI Critical Appraisal Tool for the Assessment of Risk of Bias for Quasi-Experimental Studies</article-title><source>JBI Evid. Synth.</source><year>2024</year><volume>22</volume><fpage>378</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.11124/JBIES-23-00268</pub-id><pub-id pub-id-type="pmid">38287725</pub-id></element-citation></ref><ref id="B31-vaccines-13-00964"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guyatt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oxman</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vist</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Falck-Ytter</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Glasziou</surname><given-names>P.</given-names></name><name name-style="western"><surname>deBeer</surname><given-names>H.</given-names></name></person-group><article-title>GRADE Guidelines: 1. Introduction&#8212;GRADE Evidence Profiles and Summary of Findings Tables</article-title><source>J. Clin. Epidemiol.</source><year>2011</year><volume>64</volume><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2010.04.026</pub-id><pub-id pub-id-type="pmid">21195583</pub-id></element-citation></ref><ref id="B32-vaccines-13-00964"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butow</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bartley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Milch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sathiaraj</surname><given-names>R.</given-names></name><name name-style="western"><surname>Turnbull</surname><given-names>S.</given-names></name><name name-style="western"><surname>Der Vartanian</surname><given-names>C.</given-names></name></person-group><article-title>Vaccine Hesitancy in Cancer Patients: A Rapid Review</article-title><source>Patient Educ. Couns.</source><year>2023</year><volume>111</volume><fpage>107680</fpage><pub-id pub-id-type="doi">10.1016/j.pec.2023.107680</pub-id><pub-id pub-id-type="pmid">36842287</pub-id><pub-id pub-id-type="pmcid">PMC9951090</pub-id></element-citation></ref><ref id="B33-vaccines-13-00964"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderpool</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Gaysynsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>W.-Y.S.</given-names></name><name name-style="western"><surname>Tonorezos</surname><given-names>E.S.</given-names></name></person-group><article-title>Using Behavioral Science to Address COVID-19 Vaccine Hesitancy Among Cancer Survivors: Communication Strategies and Research Opportunities</article-title><source>J. Behav. Med.</source><year>2023</year><volume>46</volume><fpage>366</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s10865-022-00304-7</pub-id><pub-id pub-id-type="pmid">35305205</pub-id><pub-id pub-id-type="pmcid">PMC8933612</pub-id></element-citation></ref><ref id="B34-vaccines-13-00964"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiderlen</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Trostdorf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Delmastro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Sp&#228;th-Schwalbe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mansmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roll</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reinwald</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>M.</given-names></name></person-group><article-title>Controlled Non-randomised before&#8211;after Study Evaluating the Impact of a Focused Recommendation Card on Vaccination Rates of Oncological Patients&#8212;The Easy Vaccination in Oncology (EVO) Strategy</article-title><source>Eur. J. Cancer Care</source><year>2022</year><volume>31</volume><fpage>e13725</fpage><pub-id pub-id-type="doi">10.1111/ecc.13725</pub-id><pub-id pub-id-type="pmid">36221170</pub-id></element-citation></ref><ref id="B35-vaccines-13-00964"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiderlen</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Trostdorf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Delmastro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Sp&#228;th-Schwalbe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mansmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roll</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reinwald</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>M.</given-names></name></person-group><article-title>Raising Immunization Rates among Cancer Patients</article-title><source>Dtsch. Arztebl. Int.</source><year>2022</year><volume>119</volume><fpage>466</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.3238/arztebl.m2022.0167</pub-id><pub-id pub-id-type="pmid">36321685</pub-id><pub-id pub-id-type="pmcid">PMC9639223</pub-id></element-citation></ref><ref id="B36-vaccines-13-00964"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivi&#232;re</surname><given-names>P.</given-names></name><name name-style="western"><surname>Penel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Faure</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Najem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivi&#232;re</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Panaget</surname><given-names>S.</given-names></name></person-group><article-title>Effect of Medical Staff Training on Vaccination Coverage in Outpatients with Cancer: An Interventional Multicenter before-and-after Study</article-title><source>Vaccine X</source><year>2023</year><volume>13</volume><fpage>100261</fpage><pub-id pub-id-type="doi">10.1016/j.jvacx.2023.100261</pub-id><pub-id pub-id-type="pmid">36654840</pub-id><pub-id pub-id-type="pmcid">PMC9841025</pub-id></element-citation></ref><ref id="B37-vaccines-13-00964"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frentiu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>H.</given-names></name><name name-style="western"><surname>May</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bronowicki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>A.</given-names></name></person-group><article-title>Vaccination for Influenza and Pneumococcus in Patients with Gastrointestinal Cancer or Inflammatory Bowel Disease: A Prospective Cohort Study of Methods for Improving Coverage</article-title><source>Aliment. Pharmacol. Ther.</source><year>2019</year><volume>49</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/apt.15057</pub-id><pub-id pub-id-type="pmid">30485467</pub-id></element-citation></ref><ref id="B38-vaccines-13-00964"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toleman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>K.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Church</surname><given-names>D.N.</given-names></name></person-group><article-title>Vaccination of Chemotherapy Patients&#8212;Effect of Guideline Implementation</article-title><source>Support. Care Cancer</source><year>2016</year><volume>24</volume><fpage>2317</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1007/s00520-015-3037-6</pub-id><pub-id pub-id-type="pmid">26610767</pub-id></element-citation></ref><ref id="B39-vaccines-13-00964"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narinx</surname><given-names>J.</given-names></name><name name-style="western"><surname>Houbiers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beguin</surname><given-names>Y.</given-names></name></person-group><article-title>Adherence to Sars-CoV2 Vaccination in Hematological Patients</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>994311</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.994311</pub-id><pub-id pub-id-type="pmid">36300128</pub-id><pub-id pub-id-type="pmcid">PMC9588907</pub-id></element-citation></ref><ref id="B40-vaccines-13-00964"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>V.-T.</given-names></name><name name-style="western"><surname>Sidorkiewicz</surname><given-names>S.</given-names></name><name name-style="western"><surname>P&#233;an</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ravaud</surname><given-names>P.</given-names></name></person-group><article-title>Impact of an Interactive Web Tool on Patients&#8217; Intention to Receive COVID-19 Vaccination: A before-and-after Impact Study among Patients with Chronic Conditions in France</article-title><source>BMC Med. Inf. Decis. Mak.</source><year>2021</year><volume>21</volume><elocation-id>228</elocation-id><pub-id pub-id-type="doi">10.1186/s12911-021-01594-8</pub-id><pub-id pub-id-type="pmcid">PMC8325218</pub-id><pub-id pub-id-type="pmid">34332570</pub-id></element-citation></ref><ref id="B41-vaccines-13-00964"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelkar</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cherabuddi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cornett</surname><given-names>H.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Cogle</surname><given-names>C.R.</given-names></name></person-group><article-title>Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar</article-title><source>Healthcare</source><year>2021</year><volume>9</volume><elocation-id>351</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare9030351</pub-id><pub-id pub-id-type="pmid">33808758</pub-id><pub-id pub-id-type="pmcid">PMC8003419</pub-id></element-citation></ref><ref id="B42-vaccines-13-00964"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGinnis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hillis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kokus</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alyafi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eiriksson</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Elit</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>A Pneumococcal Pneumonia and Influenza Vaccination Quality Improvement Program for Women Receiving Chemotherapy for Gynecologic Cancers at a Major Tertiary Cancer Centre</article-title><source>Gynecol. Oncol.</source><year>2021</year><volume>161</volume><fpage>236</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2021.01.014</pub-id><pub-id pub-id-type="pmid">33526258</pub-id></element-citation></ref><ref id="B43-vaccines-13-00964"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Church</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arfons</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jump</surname><given-names>R.</given-names></name></person-group><article-title>Improving Pneumococcal Vaccine Uptake in Veterans with Chronic Lymphocytic Leukemia through a Virtual Clinic</article-title><source>Curr. Oncol.</source><year>2018</year><volume>25</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.3747/co.25.3756</pub-id><pub-id pub-id-type="pmcid">PMC5832298</pub-id><pub-id pub-id-type="pmid">29507501</pub-id></element-citation></ref><ref id="B44-vaccines-13-00964"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delacruz</surname><given-names>W.</given-names></name><name name-style="western"><surname>Terrazzino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haney</surname><given-names>B.</given-names></name></person-group><article-title>Implementing a Multidisciplinary Approach to Enhance Compliance With Guideline-Recommended Prechemotherapy Pneumococcal Vaccination in a Military-Based Medical Oncology Practice</article-title><source>J. Oncol. Pr.</source><year>2017</year><volume>13</volume><fpage>e966</fpage><lpage>e971</lpage><pub-id pub-id-type="doi">10.1200/JOP.2016.015602</pub-id><pub-id pub-id-type="pmid">28876159</pub-id></element-citation></ref><ref id="B45-vaccines-13-00964"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivas</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Devata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khoriaty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boonstra</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Ruch</surname><given-names>J.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hernandez-Aya</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wilfong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smerage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ison</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center</article-title><source>J. Cancer Educ.</source><year>2017</year><volume>32</volume><fpage>871</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1007/s13187-016-1017-2</pub-id><pub-id pub-id-type="pmid">27055536</pub-id></element-citation></ref><ref id="B46-vaccines-13-00964"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nipp</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Ruddy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuh</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Zangardi</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Chio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.K.M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blouin</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Lage</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer</article-title><source>Oncologist</source><year>2019</year><volume>24</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0408</pub-id><pub-id pub-id-type="pmid">30341175</pub-id><pub-id pub-id-type="pmcid">PMC6369952</pub-id></element-citation></ref><ref id="B47-vaccines-13-00964"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganju</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalaiyarasi</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Karunakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Veeraiah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>N.</given-names></name></person-group><article-title>COVID-19 Vaccine Uptake in Patients with Multiple Myeloma and AL Amyloidosis: A Cross-Sectional Observational Study from India</article-title><source>Indian J. Hematol. Blood Transfus.</source><year>2024</year><volume>40</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s12288-023-01680-z</pub-id><pub-id pub-id-type="pmid">38312195</pub-id><pub-id pub-id-type="pmcid">PMC10830937</pub-id></element-citation></ref><ref id="B48-vaccines-13-00964"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro Ben David</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shamai-Lubovitz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mourad</surname><given-names>V.</given-names></name><name name-style="western"><surname>Goren</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cohen Iunger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alcalay</surname><given-names>T.</given-names></name><name name-style="western"><surname>Irony</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greenfeld</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cahan</surname><given-names>A.</given-names></name></person-group><article-title>A Nationwide Digital Multidisciplinary Intervention Aimed at Promoting Pneumococcal Vaccination in Immunocompromised Patients</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1355</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11081355</pub-id><pub-id pub-id-type="pmid">37631923</pub-id><pub-id pub-id-type="pmcid">PMC10458143</pub-id></element-citation></ref><ref id="B49-vaccines-13-00964"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozdemir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aktas</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Gulmez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inkaya</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bayraktar-Ekincioglu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kilickap</surname><given-names>S.</given-names></name><name name-style="western"><surname>Unal</surname><given-names>S.</given-names></name></person-group><article-title>Impact of Pharmacist-Led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients: A Randomized Controlled Study</article-title><source>Support. Care Cancer</source><year>2023</year><volume>31</volume><fpage>194</fpage><pub-id pub-id-type="doi">10.1007/s00520-023-07652-3</pub-id><pub-id pub-id-type="pmid">36856870</pub-id><pub-id pub-id-type="pmcid">PMC9975445</pub-id></element-citation></ref><ref id="B50-vaccines-13-00964"><label>50.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Regional Office for the Eastern Mediterranean. Health Education: Theoretical Concepts, Effective Strategies and Core Competencies: A Foundation Document to Guide Capacity Development of Health Educators</article-title><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://applications.emro.who.int/dsaf/EMRPUB_2012_EN_1362.pdf" ext-link-type="uri">http://applications.emro.who.int/dsaf/EMRPUB_2012_EN_1362.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-09-03">(accessed on 3 September 2025)</date-in-citation></element-citation></ref><ref id="B51-vaccines-13-00964"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cataldi</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kerns</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>O&#8217;Leary</surname><given-names>S.T.</given-names></name></person-group><article-title>Evidence-Based Strategies to Increase Vaccination Uptake: A Review</article-title><source>Curr. Opin. Pediatr.</source><year>2020</year><volume>32</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1097/MOP.0000000000000843</pub-id><pub-id pub-id-type="pmid">31790027</pub-id></element-citation></ref><ref id="B52-vaccines-13-00964"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name></person-group><article-title>Strategies to Increase the Coverage of Influenza and Pneumonia Vaccination in Older Adults: A Systematic Review and Network Meta-Analysis</article-title><source>Age Ageing</source><year>2024</year><volume>53</volume><fpage>afae035</fpage><pub-id pub-id-type="doi">10.1093/ageing/afae035</pub-id><pub-id pub-id-type="pmid">38476102</pub-id></element-citation></ref><ref id="B53-vaccines-13-00964"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisset</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>P.</given-names></name></person-group><article-title>Strategies for Increasing Uptake of Vaccination in Pregnancy in High-Income Countries: A Systematic Review</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>2751</fpage><lpage>2759</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.013</pub-id><pub-id pub-id-type="pmid">29661584</pub-id></element-citation></ref><ref id="B54-vaccines-13-00964"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Baggari</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ritch</surname><given-names>J.</given-names></name><name name-style="western"><surname>McIntire</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Sheffield</surname><given-names>J.S.</given-names></name></person-group><article-title>Association of a Best-Practice Alert and Prenatal Administration With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Rates</article-title><source>Obstet. Gynecol.</source><year>2015</year><volume>126</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000000975</pub-id><pub-id pub-id-type="pmid">26241423</pub-id></element-citation></ref><ref id="B55-vaccines-13-00964"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruffin</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Plegue</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rockwell</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Yeazel</surname><given-names>M.W.</given-names></name></person-group><article-title>Impact of an Electronic Health Record (EHR) Reminder on Human Papillomavirus (HPV) Vaccine Initiation and Timely Completion</article-title><source>J. Am. Board Fam. Med.</source><year>2015</year><volume>28</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.3122/jabfm.2015.03.140082</pub-id><pub-id pub-id-type="pmid">25957365</pub-id><pub-id pub-id-type="pmcid">PMC4762366</pub-id></element-citation></ref><ref id="B56-vaccines-13-00964"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puyade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hernanz</surname><given-names>M.P.G.</given-names></name><name name-style="western"><surname>Bouchaert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leleu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tourani</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Roblot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rammaert</surname><given-names>B.</given-names></name></person-group><article-title>Observational Study of Vaccination in Cancer Patients: How Can. Vaccine Coverage Be Improved?</article-title><source>Med. Mal. Infect.</source><year>2020</year><volume>50</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.medmal.2019.11.006</pub-id><pub-id pub-id-type="pmid">31848105</pub-id></element-citation></ref><ref id="B57-vaccines-13-00964"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogliastro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sticchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Domnich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zappa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Biagio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Massaro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giribaldi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Orsi</surname><given-names>A.</given-names></name></person-group><article-title>Effectiveness of a Counseling Intervention to Increase Vaccination Uptake among Men Who Have Sex with Men during the Mpox Outbreak</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>751</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12070751</pub-id><pub-id pub-id-type="pmid">39066389</pub-id><pub-id pub-id-type="pmcid">PMC11281669</pub-id></element-citation></ref><ref id="B58-vaccines-13-00964"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Biddell</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>N.T.</given-names></name></person-group><article-title>Provider Communication and HPV Vaccine Uptake: A Meta-Analysis and Systematic Review</article-title><source>Prev. Med.</source><year>2021</year><volume>148</volume><fpage>106554</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106554</pub-id><pub-id pub-id-type="pmid">33857561</pub-id></element-citation></ref><ref id="B59-vaccines-13-00964"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Shaikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Boukerdenna</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muthu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aidyralieva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bellizzi</surname><given-names>S.</given-names></name></person-group><article-title>Counselling of Non-Communicable Diseases&#8217; Patients for COVID-19 Vaccine Uptake in Jordan: Evaluating the Intervention</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>6658</fpage><lpage>6663</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.09.083</pub-id><pub-id pub-id-type="pmid">36216648</pub-id><pub-id pub-id-type="pmcid">PMC9527223</pub-id></element-citation></ref><ref id="B60-vaccines-13-00964"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasagna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alessio</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gambini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Klersy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Monaco</surname><given-names>T.</given-names></name><name name-style="western"><surname>Corallo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cicognini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pedrazzoli</surname><given-names>P.</given-names></name></person-group><article-title>Vaccine Hesitancy in Patients with Solid Tumors: A Cross-Sectional Single-Center Survey</article-title><source>BMC Public. Health</source><year>2024</year><volume>24</volume><elocation-id>2998</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-024-20468-y</pub-id><pub-id pub-id-type="pmid">39472822</pub-id><pub-id pub-id-type="pmcid">PMC11523769</pub-id></element-citation></ref><ref id="B61-vaccines-13-00964"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnstone</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smithson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>B.</given-names></name></person-group><article-title>Perspectives of Healthcare Professionals on the Pharmacist&#8217;s Role in Delivering Vaccinations for Patients with Cancer: A Qualitative Study Using Role Theory</article-title><source>Int. J. Clin. Pharm.</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s11096-025-01945-9</pub-id><pub-id pub-id-type="pmid">40522402</pub-id></element-citation></ref><ref id="B62-vaccines-13-00964"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Veettil</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kategeaw</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hutubessy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lambach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaiyakunapruk</surname><given-names>N.</given-names></name></person-group><article-title>The Impact of Pharmacist Involvement on Immunization Uptake and Other Outcomes: An Updated Systematic Review and Meta-Analysis</article-title><source>J. Am. Pharm. Assoc.</source><year>2022</year><volume>62</volume><fpage>1499</fpage><lpage>1513.e16</lpage><pub-id pub-id-type="doi">10.1016/j.japh.2022.06.008</pub-id><pub-id pub-id-type="pmcid">PMC9448680</pub-id><pub-id pub-id-type="pmid">35961937</pub-id></element-citation></ref><ref id="B63-vaccines-13-00964"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isenor</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Alia</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Slayter</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>MacDougall</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>S.K.</given-names></name></person-group><article-title>Impact of Pharmacists as Immunizers on Vaccination Rates: A Systematic Review and Meta-Analysis</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>5708</fpage><lpage>5723</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.08.085</pub-id><pub-id pub-id-type="pmid">27765379</pub-id></element-citation></ref><ref id="B64-vaccines-13-00964"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo Moro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langiano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Accortanzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cappelletti</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prinzivalli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sannella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sbaragli</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Countering Vaccine Hesitancy: A Systematic Review of Interventions to Strengthen Healthcare Professionals&#8217; Action</article-title><source>Eur. J. Public Health</source><year>2023</year><volume>33</volume><fpage>905</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckad134</pub-id><pub-id pub-id-type="pmid">37581903</pub-id><pub-id pub-id-type="pmcid">PMC10567238</pub-id></element-citation></ref><ref id="B65-vaccines-13-00964"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rand</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Humiston</surname><given-names>S.G.</given-names></name></person-group><article-title>Provider Focused Interventions to Improve Child and Adolescent Vaccination Rates</article-title><source>Acad. Pediatr.</source><year>2021</year><volume>21</volume><fpage>S34</fpage><lpage>S39</lpage><pub-id pub-id-type="doi">10.1016/j.acap.2021.02.014</pub-id><pub-id pub-id-type="pmid">33958090</pub-id></element-citation></ref><ref id="B66-vaccines-13-00964"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguolu</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Omer</surname><given-names>S.B.</given-names></name></person-group><article-title>Overcoming Vaccine Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines</article-title><source>Curr. HIV/AIDS Rep.</source><year>2022</year><volume>19</volume><fpage>328</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1007/s11904-022-00622-0</pub-id><pub-id pub-id-type="pmid">36114951</pub-id><pub-id pub-id-type="pmcid">PMC9483354</pub-id></element-citation></ref><ref id="B67-vaccines-13-00964"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuinness</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>J.P.T.</given-names></name></person-group><article-title>Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments</article-title><source>Res. Synth. Methods</source><year>2021</year><volume>12</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/jrsm.1411</pub-id><pub-id pub-id-type="pmid">32336025</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00964-f001" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA Flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00964-g001.jpg"/></fig><table-wrap position="float" id="vaccines-13-00964-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00964-t001_Table 1</object-id><label>Table 1</label><caption><p>Main characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author <break/>Publication Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year of <break/>Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study <break/>Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target of the Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Cancer </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target VPD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Multi-Component <break/>Intervention</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toleman M.S. 2015 [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#8722;2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grivas P.D. 2016 [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011&#8722;2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Natural Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP + <break/>Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delacruz W. 2017 [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#8722;2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Church E.C. 2018 [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP + <break/>Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic Lymphocytic Leukemia </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nipp R.D. 2018 [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast, gastrointestinal, or lung cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sitte J. 2018 [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8722;2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum. (Diphtheria-Tetanus-Poliomyelitis, Hepatitis b, HPV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kelkar A.H. 2021 [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020&#8722;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP + <break/>Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McGinnis J.M. 2021 [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8722;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Interrupted time series</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP + <break/>Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gynecologic </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tran V. 2021 [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kiderlen T.R. 2022 [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020&#8722;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum., Herpes Zoster and Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Narinx J. 2022 [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematologic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ganju P. 2023 [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021&#8722;2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myeloma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozdemir N. 2023 [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Turkey</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8722;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rivi&#232;re P. 2023 [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8722;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu, Pneum. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shapiro Ben David S. 2023 [<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Israel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8722;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quasi-Experimental, <break/>Pre-post evaluation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCP + <break/>Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Any</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: HCP healthcare professional, Pneum. Pneumococcal disease, VPD vaccine preventable disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00964-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00964-t002_Table 2</object-id><label>Table 2</label><caption><p>Components of the included interventions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author <break/>Publication Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient <break/>Education</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient <break/>Reminders</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patient Counselling</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCP <break/>Education</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCP <break/>Reminders</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Other</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toleman M.S. 2015 [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of vaccination guidelines *<break/>Letter for primary care providers</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grivas P.D. 2016 [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delacruz W. 2017 [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruitment of APRN to review vaccination status and prescribe vaccine if not done by oncologist</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Church E.C. 2018 [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pact between virtual clinic and primary care providers</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nipp R.D. 2018 [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sitte J. 2018 [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kelkar A.H. 2021 [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McGinnis J.M. 2021 [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In-house vaccination program; pre-printed prescriptions for prescribing physicians</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tran V. 2021 [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kiderlen T.R. 2022 [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Narinx J. 2022 [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ganju P. 2023 [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozdemir N. 2023 [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rivi&#232;re P. 2023 [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Development of a vaccination protocol</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shapiro Ben David S. 2023 [<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preapproval for PCV13 is waived </td></tr></tbody></table><table-wrap-foot><fn><p>Components marked with an asterisk (*) indicate the main component of the intervention. Abbreviations: APRN Advanced Practice Nurse Practitioner, HCP healthcare professional.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00964-t003" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00964-t003_Table 3</object-id><label>Table 3</label><caption><p>Main outcomes and results of the included interventions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">First Author <break/>Publication Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Outcomes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toleman M.S. 2015 [<xref rid="B38-vaccines-13-00964" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Vaccination coverage: Flu <break/>(2) Vaccination coverage: Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Flu: from 68.1% to 71.6% (<italic toggle="yes">p</italic> = 0.730)<break/>(2) Pneum. VC.: from 25% to 47% (<italic toggle="yes">p</italic> = 0.002)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grivas P.D. 2016 [<xref rid="B45-vaccines-13-00964" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Same day vaccination rate (Flu) (2 seasons)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Absolute increase in eligible adults vaccinated: 2.4% (<italic toggle="yes">p</italic> &lt; 0.001) and 3.7% (<italic toggle="yes">p</italic> &lt; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delacruz W. 2017 [<xref rid="B44-vaccines-13-00964" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">From 6.3% to 45.5% (<italic toggle="yes">p</italic> &lt; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Church E.C. 2018 [<xref rid="B43-vaccines-13-00964" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Within 180 days, 62% received the vaccine. Significant difference in time to vaccination between pre and post-virtual clinic periods (log-rank test, <italic toggle="yes">p</italic> &lt; 0.01).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nipp R.D. 2018 [<xref rid="B46-vaccines-13-00964" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Vaccination coverage: Flu <break/>(2) Vaccination coverage: Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Flu: intervention vs. control: 31.0% vs. 0.0% (<italic toggle="yes">p</italic> &lt; 0.001)<break/>(2) Pneum.: intervention vs. control: 37.9% vs. 0.0% (<italic toggle="yes">p</italic> &lt; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sitte J. 2018 [<xref rid="B37-vaccines-13-00964" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">From 10.1% to 87.5% (&lt;0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kelkar A.H. 2021 [<xref rid="B41-vaccines-13-00964" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) COVID-19 Vaccine intention <break/>(2) Changes in Beliefs and Perspectives on Vaccines against COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) From 71% to 82.5% (no <italic toggle="yes">p</italic>-value)<break/>(2) Increased agreeance with belief statements about vaccine effectiveness; vaccine safety; vaccine acceptance if recommended by a doctor; extra effort to receive a vaccine; and encouraging their family, friends, co-workers, and community to receive a vaccine. (no descriptive data) (<italic toggle="yes">p</italic> &lt; 0.05)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">McGinnis J.M. 2021 [<xref rid="B42-vaccines-13-00964" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Vaccination coverage: Flu <break/>(2) Vaccination coverage: Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Flu: from 36% to a monthly mean of 67% (no <italic toggle="yes">p</italic>-value)<break/>(2) Pneum. VC.: from 5% to a monthly mean of 61% (no <italic toggle="yes">p</italic>-value)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tran V. 2021 [<xref rid="B40-vaccines-13-00964" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19 Vaccine intention</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Among the cancer patients who did not intend to be vaccinated at baseline, 18.0% changed their mind (<italic toggle="yes">p</italic>-value)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kiderlen T.R. 2022 [<xref rid="B34-vaccines-13-00964" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention vs. control: VC increase +21.5pp vs. &#8722;5.8pp <break/>(OR 4.94, 95% CI 1.76&#8211;13.83, <italic toggle="yes">p</italic> = 0.002)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Narinx J. 2022 [<xref rid="B39-vaccines-13-00964" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (COVID-19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination rates: 88.9% among patients of the intervention group; 76.3% in the general population (control) (Standardized Incidence ratio: 1.17; 95%CI 1.12&#8722;1.22, <italic toggle="yes">p</italic> &lt; 0.001) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ganju P. 2023 [<xref rid="B47-vaccines-13-00964" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (COVID-19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> At least one dose: 86% (2 doses: 67%) (no comparisons, no <italic toggle="yes">p</italic>-value)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozdemir N. 2023 [<xref rid="B49-vaccines-13-00964" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Pneum. vaccination knowledge (higher score = higher number of correct answers)<break/>(2) Vaccination Attitudes Examination (VAX) score (higher score = higher negative attitude)<break/>(3) Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Intervention vs. control: median 10 (IQR = 3) vs. 8 (IQR = 4) (<italic toggle="yes">p</italic> &lt; 0.001)<break/>(2) Intervention vs. control: mean 33.09 (SD = 7) vs. 36.07 (SD = 6.5) (<italic toggle="yes">p</italic> = 0.007)<break/>(3) Intervention vs. control: 20.2% vs. 6.1% (<italic toggle="yes">p</italic> = 0.003)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rivi&#232;re P. 2023 [<xref rid="B36-vaccines-13-00964" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Vaccination coverage: Flu <break/>(2) Vaccination coverage: Pneum.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1) Flu VC: from 42.6% to 55.1% (<italic toggle="yes">p</italic> = 0.08)<break/>(2) Pneum. VC: from 11.8% to 15.4%, (<italic toggle="yes">p</italic> =1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shapiro Ben David S. 2023 [<xref rid="B48-vaccines-13-00964" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccination coverage (Pneum.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCV13: from 11.9% to 52% (<italic toggle="yes">p</italic> &lt; 0.001)<break/>PPSV23: from 39.4% to 57.1% (<italic toggle="yes">p</italic> &lt; 0.001)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CI Confidence Interval, IQR Interquartile Range, OR Odds Ratio, Pneum. Pneumococcal disease, SD Standard Deviation, VC Vaccination Coverage.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>